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Behçet’s disease is a chronic relapsing multisystemic inflammatory disorder char-
acterized by four major symptoms (oral aphthous ulcers, genital ulcers, skin le-
sions, and ocular lesions) and occasionally by five minor symptoms (arthritis, gas-
trointestinal ulcers, epididymitis, vascular lesions, and central nervous system 
symptoms). Although the etiology of Behçet’s disease is still unknown, there have 
been recent advances in immunopathogenic studies, genome-wide association 
studies, animal models, diagnostic markers, and new biological agents. These ad-
vances have improved the clinical understanding of Behçet’s disease and have en-
abled us to develop new treatment strategies for this intractable disease, which re-
mains one of the leading causes of blindness.
Key Words:    Behçet’s disease, epidemiology, etiopathogenesis, animal model, di-
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INTRODUCTION
The clinical manifestations of Behçet’s disease were described by Hippocrates in 
the fifth century BC.1 However, in 1937, Turkish dermatologist Hȗlusi Behçet was 
the first to comprehensively describe the symptom complex of recurrent oral aph-
thous ulcers, genital ulcers, and uveitis as a disease entity with the suggestion of a 
possible viral etiology.2
Although there are many synonyms for the condition, including triple symptom 
complex,3 syndrome de Behçet,4 Behçet’s disease,5 Adamantiades-Behçet’s syn-
drome,6 Behçet’s multiple symptom complex,7 Behçet’s syndrome, Adamantiades-
Behçet’s disease, mucocutaneous-ocular syndrome,8 mouth and genital ulcers with 
inflamed cartilage syndrome,9 and pseudo-Behçet’s syndrome,10 Behçet’s disease 
is the most commonly agreed upon terminology,11-13 and the representative interna-
tional society on this disease uses the term Behçet’s disease.
EPIDEMIOLOGY
Behçet’s disease exists worldwide although there are significant regional differenc-
es, with the highest number of incidences in the Mediterranean, the Middle East, 
and the Far East (Fig. 1, Table 1).10 The association of Behçet’s disease with the Sung Bin Cho, et al.
Yonsei Med J   http://www.eymj.org   Volume 53   Number 1   January 2012 36
den, Portugal, and the United States, ranging from 0.3 to 6.4 
per 100,000 persons.19-26 The numbers of patients with Be-
hçet’s disease registered by the National Health Insurance 
Corporation of Korea have been increasing. As of 2006, 
15,554 patients with Behçet’s disease (5,499 males and 
10,055 females, 30.2/100,000 people) were registered with 
the Center for Genetic & Rare Diseases (Korea Centers for 
Disease Control and Prevention, Seoul, Korea).16 
The onset of Behçet’s disease typically occurs in the third 
or fourth decade of life, and it is rarely seen in children or pa-
tients above the age of 50. The clinical courses of childhood-
onset Behçet’s disease and late-onset Behçet’s disease are 
relatively benign.16,21,24,27,28 The average time between the 
initial appearance of the first major symptom, usually oral 
ulcerations, and the development of a second major symp-
tom in children is 8.8 years.27 The incidence of panuveitis de-
creases as age increases, while the incidence of anterior uve-
itis increases with age.28 Familial cases have been reported.29
Behçet’s disease shows a male preponderance in Middle 
Eastern countries and the Mediterranean basin; however, 
women are more commonly affected in Japan and Ko-
rea.11,22,24,30 The mean age of onset for patients with the worst 
prognoses, such as those with ocular, gastrointestinal, neu-
rologic, and vascular involvement, is significantly younger 
in males than in females.30 Behçet’s disease was exacerbat-
ed in 67% of pregnant women and improved in 33%. In pa-
tients who experienced worsening of the disease during 
pregnancy, clinical exacerbation occurred most commonly 
ancient trading route known as the “Silk Road” and the dis-
tribution of HLA-B5 and its HLA-B*51 subtype provides 
important clues to its origin. Behçet’s disease occurs most 
frequently between the latitudes 30o and 45o N in Eurasian 
populations.14-16 Although there are reports of Behçet’s dis-
ease from other parts of the world including Mongolia, 
Russia, Brazil, Mexico, Columbia, Argentina, Chile, Cuba, 
Australia, and New Zealand, these reports total less than 
200 patients.15,17 Behçet’s disease may be an under-reported, 
HLA-B51 negative condition and is often life-threatening 
and/or associated with severe damage in native East African 
populations.18 Turkey demonstrates the highest prevalence of 
Behçet’s disease in the world, with up to 421 per 100,000 
persons affected. Iran, Israel, northern China, and Korea 
follow with the next highest prevalence. The countries with 
the lowest prevalence are the United Kingdom, Spain, Swe-
Table 1. Countries with High Prevalence of Behçet’s Disease
Country Prevalence per 10
5 population
Turkey [Istanbul (urban)]
20  420
Israel (Druze)
20     146.4
Northern China
20  110
Iran
15   80
Korea
16      30.2
Japan (Hokkaido)
20    22
Saudi Arabia
20    20
Iraq
20    17
Morocco
14 >15
Egypt
20         7.6
Fig. 1. Global distribution of Behçet’s disease. Dot size reflects prevalence.
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is known as an anti-inflammatory cytokine that inhibits the 
action of proinflammatory cytokines, and the up-regulation 
of the CD4+ CD25+ T-regulatory cells in a Behçet’s disease-
like mouse model improved the inflammatory symptoms 
via IL10.38 Therefore, the IL10 and IL23R-IL12B2 genes 
may play major roles in the pathogenesis of Behçet’s dis-
ease.
Autoimmune or autoinflammatory reactions in Behçet’s 
disease are suggested to target primarily blood vessels, es-
pecially endothelial cells, causing the clinical presentation 
of vasculitis and/or thrombosis symptoms. Lee, et al.39 iden-
tified α-enolase as a target antigen of IgM-type anti-endo-
thelial cell antibodies (AECA) in patients with Behçet’s 
disease using proteomic techniques. Several mechanisms 
were proposed in order to explain the action of AECAs in 
the pathophysiology of inflammatory diseases, including 
the binding of AECA to endothelial cells resulting in cell 
activation, which may in turn increase secretions of che-
moattractants and/or cytokines as well as secretion or inhi-
bition of prostacyclin. AECAs might also trigger inflamma-
tory processes by complement-dependent cytotoxicity and/
or antibody-dependent cellular toxicity. 
Infectious agents, especially herpes simplex virus (HSV) 
and Streptococcus sanguis (S. sanguis), have long been pos-
tulated as possible environmental triggers of Behçet’s dis-
during the first trimester, in about 78% of cases.31
ETIOPATHOGENESIS
The exact etiopathogenesis of Behçet’s disease has not been 
clarified. However, many studies indicate that the disease 
may be triggered by environmental factors, such as infec-
tious agents or pollution, in patients with backgrounds of 
genetic susceptibility (Fig. 2).25,32,33 Studies have shown that 
HLA-B*51 is associated with Behçet’s disease, with more 
than 60% of patients with Behçet’s disease testing positive 
for HLA-B*51.34 Recently, two reports of genome-wide as-
sociation studies revealed that the MHC region of chromo-
some 6 was strongly associated with Behçet’s disease, and 
HLA-B*51 is regarded as the primary association to Be-
hçet’s disease within the MHC region.34-36 In addition, me-
ta-analyses identified that common variants of the IL10 and 
encoding interleukin 23 receptor (IL23R)-encoding inter-
leukin 12 receptor beta (IL12B2) genes were strongly asso-
ciated with Behçet’s disease.35,36 IL23 is a proinflammatory 
cytokine that stimulates Th17 proliferation, increases the 
production of inflammatory cytokines, and increases the 
expression of IL-23 p19 mRNA in erythema nodosum-like 
skin lesions in patients with active Behçet’s disease.34,37 IL10 
Fig. 2. Diagram presenting etiopathogenesis of Behçet’s disease. TNF, tumor necrosis factor; IL, interleukin; CTLA-4, cytotoyic T-lymphocyte 
antigen-4.
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tem, and “bacterial persistence” or autoantigen-activated an-
tigen-presenting cells are required to sustain the inflammato-
ry reaction mediated by the adaptive immune system.45
 
 
DIAGNOSIS AND CLINICAL 
MANIFESTATIONS
Because Behçet’s disease has no pathognomonic laboratory 
findings or histological characteristics, diagnoses are made 
according to clinical criteria proposed by the International 
Study Group for Behçet’s Disease47 or the Behçet’s Disease 
Research Committee of Japan.48 Recurrent oral ulcers are the 
most frequently observed major symptom in Behçet’s dis-
ease. However, it is difficult to differentiate between recur-
rent aphthous stomatitis (RAS) and recurrent oral ulcers in 
Behçet’s disease.49 Patients with Behçet’s disease are at a 
higher risk of major types of oral ulcers (deep and >10 mm 
in diameter) and a lower risk of minor types of ulcers (shal-
low and <10 mm in diameter) than are RAS patients.49 Pa-
tients with Behçet’s disease more commonly have ulcers on 
two or more sites of the oral mucosa compared with RAS pa-
tients. Because minor symptoms, especially articular symp-
toms, are more commonly associated with Behçet’s disease, 
RAS patients with additional major or minor symptoms 
should be monitored carefully for any progression to Be-
hçet’s disease.49
Diagnosing minor features that correlate with Behçet’s 
disease is difficult because major manifestations emerge at 
different points in time throughout the course of the disease. 
Involvements of the gastrointestinal tract, vascular system, 
or central nervous system are closely correlated with mor-
tality and morbidity, although life-threatening complica-
tions such as intestinal perforation, arterial occlusion, and 
aneurysm rupture are less frequent. However, the systemic 
manifestations of Behçet’s disease lack reliable diagnostic 
criteria. Cheon, et al.50 reported novel diagnostic criteria for 
intestinal Behçet’s disease in Korean patients with ileoco-
lonic ulcers. Intestinal Behçet’s disease was categorized into 
four groups: 1) definite (typical intestinal ulcers in colonos-
copy plus complete, incomplete, or suspected types of Be-
hçet’s disease); 2) probable (typical intestinal ulcers in colo-
noscopy plus typical recurrent oral ulcers or atypical intestinal 
ulcers and complete, incomplete, or suspected types of Be-
hçet’s disease); 3) suspected (typical intestinal ulcers in 
colonoscopy without any extraintestinal symptoms or atypi-
cal intestinal ulcers plus typical recurrent oral ulcers); 4) and 
ease. Patients with Behçet’s disease have significantly high-
er levels of S. sanguis in their oral flora than do healthy 
controls or patients with other diseases.33,40 Patients with Be-
hçet’s disease also show strong delayed cutaneous hyper-
sensitivity reactions as well as oral aphthous ulcerations 
against streptococcal antigens after skin injection or oral 
prick tests with streptococcal antigens. Kaneko, et al.33 sug-
gested that the Bes-1 gene and streptococcal 65 kDa heat 
shock protein from an uncommon serotype (KTH-1, strain 
BD113-20) of oral S. sanguinis are important extrinsic fac-
tors in the pathogenesis of Behçet’s disease. Sera from pa-
tients with Behçet’s disease, which react with recombinant 
human α-enolase, were revealed by proteomic techniques 
to cross-react with streptococcal α-enolase.40
HSV type 1 can be detected in saliva, intestinal ulcers, 
and genital ulcers by polymerase chain reaction in patients 
with Behçet’s disease compared with healthy controls.41,42 
In addition, a Behçet’s disease-like mouse model was de-
veloped by inoculation of ICR mouse earlobes with HSV 
and demonstrated HSV DNA sequences in cutaneous and 
gastrointestinal ulcerative lesions.42 Although pretreatment 
or concurrent treatment with famciclovir in ICR mice could 
not prevent the development of Behçet’s disease-like symp-
toms after HSV inoculation, famciclovir seemed to be ef-
fective in improving Behçet’s disease-like symptoms and 
preventing recurrence in a symptomatic mouse model.43 
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is a costimu-
latory molecule in T cells that plays a crucial role in immuno-
regulation, and reduced expression of CTLA-4 has been dem-
onstrated in various autoimmune or autoinflammatory 
disorders.44 In patients with Behçet’s disease, the role of se-
rum soluble CTLA-4 levels and the associations between 
CTLA-4 polymorphisms and disease susceptibility have been 
reported.44 Recently, Sim, et al.44 reported that reduced expres-
sion of CTLA-4 in CD4+ T cells was observed in patients 
with active Behçet’s disease after stimulation. In addition, de-
creased expression of CD86 and programmed death-ligand 1 
were found in patients with active Behçet’s disease.44 
Behçet’s disease has been described as both an autoim-
mune and an autoinflammatory disorder.45 Autoinflammatory 
diseases refer to inherited disorders characterized by episodes 
of recurrent inflammatory reactions of the innate immune 
system without remarkable provocation, especially by neu-
trophils; whereas autoimmune diseases present with signifi-
cant levels of high-titer autoantibodies or antigen-specific T-
cells.46 Infectious agents are suggested as triggering the 
inflammatory reaction mediated by the innate immune sys-Behçet’s Disease
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pirical, but is generally specific to the clinical features of each 
patient.15,16,22,24,56-66 The appropriate management of Behçet’s 
disease requires a multidisciplinary approach. Although 
various therapeutic modalities have been employed for Be-
hçet’s disease, the results of treatment are far from satisfac-
tory. There is still no single effective drug for Behçet’s dis-
ease in any clinical state. For evaluations of therapeutic 
efficacy, it is difficult to compare the results of different stud-
ies, and it is impossible to pool the results for calculating 
the effect sizes of treatment modalities due to the paucity of 
randomized controlled trials as well as the variability of the 
natural course of the disease and the limited number of cas-
es available for clinical investigation.16 
Despite limitations in the evaluation of therapeutic efficacy 
against Behçet’s disease, treatment of Behçet’s disease has 
become much more effective in recent years because of ad-
vances in disease pathogenesis and the increasing availability 
of a wide spectrum of therapeutic agents. Recently, a group 
of experts developed nine recommendations for the manage-
ment of Behçet’s disease by combining current evidence 
from controlled trials.59,60 The European League Against 
Rheumatism recommendations for the management of Be-
hçet’s disease suggests that recommendations related to the 
eye, skin-mucosa disease and arthritis are mainly evidence 
based, but that recommendations on vascular disease, neu-
rological and gastrointestinal involvement are based largely 
on expert opinion and the results of uncontrolled open trials 
and observational studies.59 Corticosteroids are commonly 
used to treat clinical manifestations of Behçet’s disease as a 
monotherapy or in combination with immunosuppressants. 
Although they have beneficial effects against acute inflam-
mation, no definite evidence has indicated that they are ef-
fective for controlling progression of the disease, and the ad-
verse effects of long-term use must always be considered. 
Tumor necrosis factor (TNF)-blocking agents such as inf-
liximab, etanercept, and adalimumab have been reported to 
have some success in patients with Behçet’s disease who 
have mucocutaneous or gastrointestinal lesions, neurologi-
cal disease, or even pulmonary aneurysms.22,67 There is 
enough published experience to suggest that TNF blockade 
represents an important therapeutic advance for patients 
with severe disease who are resistant to standard immuno-
suppressive regimens and for those patients with contrain-
dications or intolerance to these treatments.67 However, the 
high cost, need for injections, troublesome toxic side ef-
fects, and lack of long term evidence for therapeutic effica-
cy are the main limitations to the widespread acceptance of 
nondiagnostic (atypical intestinal ulcers without extraintes-
tinal manifestations).50 
18F-fluorodeoxyglucose positron emission tomography 
(FDG-PET) or PET/computed tomography (CT) is widely 
used for diagnosing diseases other than malignancies, in-
cluding various causes of arthritis and vascular diseases. 
However, there have been few reports describing the clinical 
efficacy of using FDG-PET or PET/CT for diagnosing Be-
hçet’s disease.51,52 Denecke, et al.51 described the inflamma-
tory activity of pulmonary artery aneurysms detected by 
FDG-PET/CT in patients with Behçet’s disease. In addi-
tion, we reported eight patients with Behçet’s disease with 
FDG uptake in cardiovascular lesions associated with Be-
hçet’s disease, including multiple pseudoaneurysms, aorti-
tis, and arteritis associated with aortic regurgitation and an-
eurysmatic dilatation of the sinus of Valsalva, atherosclerotic 
changes of the proximal ascending aorta associated with 
aortic regurgitation, and multiple pulmonary artery aneu-
rysms.52 Although these reports do not indicate that FDG-
PET or PET/CT are necessary to diagnose patients with Be-
hçet’s disease, FDG-PET or PET/CT, which may be used to 
scan the entire body, may have clinical value as baseline 
workup tools against Behçet’s disease if there is suspicion 
of associated malignancy or internal organ involvement.
Disease activity of Behçet’s disease has been calculated 
clinically using the Behçet’s Disease Current Activity Form 
2006 (www.behcet.ws/pdf/BehçetsDiseaseActivityForm.
pdf). However, because there are no novel laboratory mark-
ers that reflect disease activity in patients with Behçet’s dis-
ease, serum erythrocyte sedimentation rate and C-reactive 
protein have been used to assess disease activity and clinical 
responses to treatment.53 In addition, S100A12, which con-
tributes to the pathogenesis of Behçet’s disease and is relat-
ed to neutrophil hyperactivity, may reflect disease activity in 
Behçet’s disease.54 Persistently high anti-streptolysin O 
(ASO) titers in patients with Behçet’s disease indicate that 
streptococcal infections such as tonsillitis may be related to 
Behçet’s disease symptoms, especially erythema nodosum-
like skin lesions. In these patients, ASO titers can be used 
for the evaluation of disease activity, and antibiotic treat-
ments might be effective for controlling the symptoms of 
Behçet’s disease.55
 
TREATMENT
 
The treatment of Behçet’s disease is symptomatic and em-Sung Bin Cho, et al.
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than single agent regimens. The most effective management 
involves early diagnosis and clinical intervention with con-
tinuous follow-up. Consequently, it may be possible to re-
duce the risk of serious complications and socioeconomic 
costs due to Behçet’s disease. The therapeutic approach to 
Behçet’s disease is summarized in Fig. 3. However, further 
studies are still necessary to find the most appropriate thera-
py and diagnostic markers to overcome this rare, intractable 
disease, which often leads to blindness and fatal systemic 
involvement.
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anti-TNF-α agents as a first-line choice for Behçet’s disease 
management. The adverse effects of anti-TNF-α agents in-
clude infection, autoimmune reactions, lymphoproliferative 
disorders, delayed hypersensitivity reactions, as well as neu-
rologic, cardiac, and gastrointestinal symptoms. In addition, 
cases of relapse and new onset of uveitis during anti-TNF-α 
treatments have been reported. The mechanism of new on-
set uveitis is not well known thus far.68,69
Nowadays, there are some optimistic viewpoints about 
managing Behçet’s disease because researches to reveal the 
pathogenesis and to develop new therapeutic agents are ac-
tively being held. In an effort, immune tolerance utilizing 
the peptides of Hsp-65/60 has recently been considered as a 
possible new therapy for patients with Behçet’s disease.70 
The fact that the most typical cases of Behçet’s disease, 
those with all of the 4 major symptoms, have been decreas-
ing in Japan, although the reason remains uncertain, may be 
another relatively good news.71 
Therapeutic agents should be selected after thorough eval-
uations of immune status through a variety of tests and after 
determining any aggravating or provoking factors. Combi-
nation regimens are generally accepted to be more effective 
Fig. 3. Therapeutic approach to Behçet’s disease. TNF, tumor necrosis factor; IFN, interferon.
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